William Blair analyst Andy Hsieh has reiterated their bullish stance on CRBP stock, giving a Buy rating on July 30.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andy Hsieh has given his Buy rating due to a combination of factors that highlight Corbus Pharmaceuticals’ promising outlook. The company is entering a period rich with catalysts, as it is set to release data for all three of its key assets in oncology and obesity by the end of the year. This includes the Phase I results for CRB-913, a cannabinoid type-1 receptor inverse agonist targeting obesity, with an emphasis on monitoring psychiatric adverse events.
Additionally, the upcoming release of Phase I/II trial results for CRB-701, an anti-nectin 4 antibody-drug conjugate, at the European Society for Medical Oncology meeting, and the expected announcement of Phase I data for CRB-601, an anti-αvβ8 antibody, further bolster the company’s potential. Corbus’ strong cash position, with $116.6 million at the end of the second quarter, is projected to support operations through mid-2027, providing financial stability as the company advances its clinical programs.
In another report released on July 30, B.Riley Financial also maintained a Buy rating on the stock with a $28.00 price target.